A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus

A Gupta, Carmine Monteferrante, D Rasina, G Leitis, CP Randall, JH Tomlinson, A Jirgensons, Wil Goessens, John Hays, AJ O'Neill

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)


GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II clinical trials. Here, we report the identification of a clinical isolate of Staphylococcus aureus that exhibits reduced susceptibility to GSK2251052 without prior exposure to the compound and demonstrate that this phenotype is attributable to a single amino acid polymorphism (P-329) within the editing domain of LeuRS.
Original languageUndefined/Unknown
Pages (from-to)3219-3221
Number of pages3
JournalAntimicrobial Agents & Chemotherapy
Issue number5
Publication statusPublished - 2016

Research programs

  • EMC MM-04-28-01

Cite this